Beam Therapeutics annual debt-to-assets ratio
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Debt-to-Assets Ratio Growth & History (BEAM)
Beam Therapeutics's debt-to-assets ratio was 0.10 for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.10 | −0.04 | −28.85% |
| 2024 | 2024-12-31 | 0.15 | 0.03 | +23.62% |
| 2023 | 2023-12-31 | 0.12 | −0.02 | −12.79% |
| 2022 | 2022-12-31 | 0.14 | 0.04 | +35.47% |
| 2021 | 2021-12-31 | 0.10 | −0.14 | −57.98% |
| 2020 | 2020-12-31 | 0.24 | 0.04 | +19.09% |
| 2019 | 2019-12-31 | 0.20 | — | — |
Beam Therapeutics quarterly debt-to-assets ratio
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.18 | 0.07 | +60.34% |
| Q1 2026 | 2026-03-31 | 0.17 | 0.06 | +57.13% |
| Q4 2025 | 2025-12-31 | 0.10 | −0.04 | −28.85% |
| Q3 2025 | 2025-09-30 | 0.12 | −0.02 | −16.52% |
| Q2 2025 | 2025-06-30 | 0.11 | −0.02 | −15.06% |
| Q1 2025 | 2025-03-31 | 0.11 | −0.02 | −12.81% |
| Q4 2024 | 2024-12-31 | 0.15 | 0.03 | +23.62% |
| Q3 2024 | 2024-09-30 | 0.14 | 0.00 | +2.63% |
| Q2 2024 | 2024-06-30 | 0.13 | 0.00 | +0.14% |
| Q1 2024 | 2024-03-31 | 0.12 | −0.01 | −7.90% |
| Q4 2023 | 2023-12-31 | 0.12 | −0.02 | −12.79% |
| Q3 2023 | 2023-09-30 | 0.13 | 0.00 | +1.98% |
| Q2 2023 | 2023-06-30 | 0.13 | 0.01 | +4.44% |
| Q1 2023 | 2023-03-31 | 0.13 | 0.03 | +29.96% |
| Q4 2022 | 2022-12-31 | 0.14 | 0.04 | +35.47% |
| Q3 2022 | 2022-09-30 | 0.13 | 0.01 | +5.12% |
| Q2 2022 | 2022-06-30 | 0.13 | −0.03 | −21.58% |
| Q1 2022 | 2022-03-31 | 0.10 | −0.09 | −47.57% |
| Q4 2021 | 2021-12-31 | 0.10 | −0.14 | −57.98% |
| Q3 2021 | 2021-09-30 | 0.13 | 0.00 | +1.93% |
| Q2 2021 | 2021-06-30 | 0.16 | 0.04 | +32.39% |
| Q1 2021 | 2021-03-31 | 0.20 | 0.09 | +77.82% |
| Q4 2020 | 2020-12-31 | 0.24 | 0.04 | +19.09% |
| Q3 2020 | 2020-09-30 | 0.12 | — | — |
| Q2 2020 | 2020-06-30 | 0.12 | — | — |
| Q1 2020 | 2020-03-31 | 0.11 | — | — |
| Q4 2019 | 2019-12-31 | 0.20 | — | — |
Beam Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, Beam Therapeutics's debt-to-assets ratio decreased from 0.24 to 0.10, a change of −0.13. The latest reported quarter, Q2 2026, shows 0.18.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...